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ABSTRACT There remains an unmet need for effective, well-tolerated therapeutic options in paediatric
patients with not fully controlled asthma, for whom safety is of paramount importance.
Data were pooled from five randomised, double-blind, placebo-controlled studies evaluating tiotropium 5 or
2.5 µg versus placebo add-on therapy in patients with symptomatic asthma aged 1–17 years. Analysis included
adverse events (AEs) and serious AEs (SAEs) reported throughout and for 30 days following treatment.
Of 1691 patients treated, 1119 received tiotropium. Reporting of AEs was low and comparable across all
groups: tiotropium 5 µg (51%), tiotropium 2.5 µg (51%) and placebo (54%). Reporting of drug-related AEs,
those leading to discontinuation and SAEs was also low and balanced between treatment groups, irrespective
of age, disease severity or sex. The number of AEs related to asthma symptoms and exacerbations was lower
with tiotropium (5 µg) than with placebo, particularly during the seasonal peaks of these AEs.
This comprehensive analysis of a large safety database allowed subgroup analyses that are often
impractical with individual trials and provides further support for the safety of once-daily tiotropium
Respimat add-on therapy in paediatric patients with symptomatic asthma.
This article has supplementary material available from erj.ersjournals.com
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Introduction
Asthma is one of the most prevalent chronic diseases in children and adolescents, affecting ∼10% of
children and adolescents in the UK and USA [1–3]. Studies have shown that >50% of 4–18-year-old
patients with asthma remain symptomatic despite treatment with at least an inhaled corticosteroid
(ICS) [1, 2]. For these patients, the first intervention is to improve patient education and self-management.
This involves ensuring adherence to the prescribed treatment and optimal use of the device, and, where
possible, confirming the avoidance of allergens and exposure to environmental pollutants and tobacco
smoke. Should symptoms persist, step-up treatments may be considered. Treatment options include
addition of a long-acting β2-agonist (LABA) and/or a leukotriene receptor antagonist (LTRA) to the
maintenance treatment regimen and/or a further increase in the dose of ICS [4]. ICS therapy is shown to
affect growth in children, particularly when administered in medium-to-high doses over an extended
period of time; thus, an alternative to increasing the ICS dose would be attractive [5, 6]. Common
side-effects associated with LABAs include increased heart rate, palpitations and tremor, although tremor
commonly resolves after the first few doses [7]. The LTRA montelukast has generally been regarded as safe
for use in children, although inferior to ICS in terms of efficacy [8]. Conversely, a study utilising the
Swedish database for adverse drug reactions, SWEDIS, which investigated drug groups commonly used in
children, has shown that montelukast was the drug with the most frequent adverse drug reactions in 2005.
The majority of these were in children <5 years old and were predominately psychiatric in nature [9].
Another study has also highlighted some specific neuropsychiatric adverse events (AEs), of which users
should be cognisant [10]. Therefore, there is an unmet need for more well-tolerated and efficacious
therapeutic options for the treatment of paediatric patients with symptomatic asthma.
Tiotropium Respimat (Boehringer Ingelheim, Ingelheim am Rhein, Germany) (hereafter referred to as
“tiotropium”) is a long-acting muscarinic antagonist. It has been evaluated as an add-on therapy in a
comprehensive phase 2 and 3 clinical trial programme including more than 6000 adult and paediatric
patients with symptomatic asthma [11–24]. Based on the evidence from these trials, tiotropium is an
efficacious add-on therapy, with safety and tolerability comparable with placebo in the individual studies.
Tiotropium is indicated for once-daily use in the European Union (two inhalations of 2.5 µg) and USA
(two inhalations of 1.25 µg) as maintenance treatment in patients with severe asthma aged ⩾6 years
[25, 26]. In addition to the safety reports of tiotropium add-on therapy from the individual clinical trials,
and an in-depth, systematic assessment of safety and tolerability in adult patients [27, 28], the analysis
presented here, involving a large sample of paediatric patients, can provide greater power to detect any
as-yet unidentified safety signals, and allows the analysis of safety in subgroups that is impractical with
individual trials.
The aim of the current analysis, therefore, was to further assess the safety and tolerability of tiotropium
from a pooled population of paediatric (1–17 years) patients with symptomatic asthma at different Global
Initiative for Asthma (GINA) treatment steps, and to investigate the seasonality of AEs relating to asthma
exacerbations and symptoms in the pooled populations.
Methods
This pooled analysis included all phase 3 parallel-group studies in children (6–11 years) and adolescents
(12–17 years), as well as a phase 2/3 study in children aged 1–5 years, included in the clinical development
programme of tiotropium in asthma. All trials were of randomised, double-blind, placebo-controlled
design, and between 12 weeks and 1 year in duration (table 1) [18, 19, 21–23]. The treatment history
(treatment step on enrolment) specified in each trial differed and reflected the severity of the patient
population (table 1).
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TABLE 1 Overview of study designs and key inclusion/exclusion criteria
NinoTinA-asthma [23] CanoTinA-asthma [21] VivaTinA-asthma [20] RubaTinA-asthma [17] PensieTinA-asthma [18]
ClinicalTrials.gov
identifier
NCT01634113 NCT01634139 NCT01634152 NCT01257230 NCT01277523
Phase and design# Phase 2/3 Phase 3, randomised,
double-blind, placebo-controlled,
parallel-group





Phase 3, randomised, double-blind,
placebo-controlled, parallel-group
Objectives Efficacy and safety Efficacy and safety Efficacy and safety Efficacy and safety Efficacy and safety










History of asthma NA ⩾6 months ⩾6 months ⩾3 months ⩾3 months
Symptomatic asthma Daytime symptoms more than









Stable ICS, with or without
another controller, for
⩾4 weeks before screening
Medium-dose ICS (200–
400 μg·day−1 budesonide or
equivalent dose), with or without
another controller, for ⩾4 weeks
before screening; LABA had to be
discontinued ⩾24 h prior to
screening
High-dose ICS (>400 μg·day−1
budesonide or equivalent dose) plus
⩾1 controller or medium-dose ICS
(200–400 μg·day−1 budesonide or
equivalent dose) plus ⩾2 controllers
for ⩾4 weeks before screening
Medium-dose ICS (400–
800 μg·day−1 budesonide or
equivalent dose), with or without
LTRA, for ⩾4 weeks before
screening; LABA had to be
discontinued ⩾72 h prior to
screening
High-dose ICS (800–1600 μg·day−1
budesonide or equivalent dose) plus
⩾1 controller or medium-dose ICS
(400–800 μg·day−1 budesonide or
equivalent dose) plus ⩾2 controllers
for ⩾4 weeks before screening
Pre-bronchodilator
FEV1 % pred at
screening
⩽90% for 5-year-olds 60–90% 60–90% 60–90% 60–90%
FEV1 reversibility at
screening
⩾12%, 15–30 min after 200 μg
salbutamol
⩾12%, 15–30 min after 200 μg
salbutamol
⩾12% and ⩾200 mL, 15–30 min
after 400 μg salbutamol (age
>14 years) or ⩾12% only (age 12–
14 years)
⩾12% and ⩾200 mL, 15–30 min after
400 μg salbutamol (age >14 years) or




±30% ±30% ±30% ±30%
Smoking history Nonsmoker or ex-smoker who
stopped smoking ⩾1 year prior to
enrolment
Nonsmoker or ex-smoker who
stopped smoking ⩾1 year prior to
enrolment
Exclusion criteria Significant disease other than
asthma
Significant disease other than
asthma
Significant disease other than
asthma
Significant disease other than
asthma
Significant disease other than
asthma
Treatment Once-daily tiotropium (5 or
2.5 µg) or placebo+
Once-daily tiotropium (5 or 2.5 µg)
or placebo
Once-daily tiotropium (5 or 2.5 µg)
or placebo
Once-daily tiotropium (5 or
2.5 µg) or placebo
Once-daily tiotropium (5 or 2.5 µg) or
placebo
Treatment duration 12 weeks 48 weeks 12 weeks 48 weeks 12 weeks
Sample size 102 randomised patients (101
treated, 102 planned); 101
completed patients
403 randomised patients (401
treated, 385 planned); 384
completed patients
401 randomised patients (400
treated, 375 planned); 392
completed patients
398 randomised patients (397
treated, 127 planned per group);
376 completed patients
392 randomised patients (392
treated, 375 planned); 388 completed
patients
NA: not applicable; ACQ: Asthma Control Questionnaire; IA: interviewer-administered; ICS: inhaled corticosteroid; LTRA: leukotriene receptor antagonist; LABA: long-acting β2-agonist;
FEV1: forced expiratory volume in 1 s; % pred: % predicted. #: note that NinoTinA-asthma was a phase 2/3 trial; ¶: the study allowed variation of absolute FEV1 values for visit 1
(pre-bronchodilator) compared with visit 2 (pre-dose) within ±30%; +: in the NinoTinA-asthma study, patients aged 1–4 years at visit 1 were required to use an Aerochamber Plus Flow-Vu
valved holding chamber (commonly referred to as a spacer) with a face mask for the inhalation of trial medication to reduce variability and ensure standardised dosing, whereas children


















During the treatment period in all trials, patients received tiotropium (5 or 2.5 µg) or placebo (delivered by
a Respimat inhaler as two puffs) once daily. Tiotropium was administered as add-on therapy to ICS
maintenance treatment with or without other controller therapies. In the NinoTinA-asthma study [23],
patients aged 1–4 years at screening were required to use an Aerochamber Plus Flow-Vu valved holding
chamber (commonly referred to as a spacer; Trudell Medical International, London, ON, Canada) with a
face mask for the inhalation of trial medication. Children aged 5 years at screening were permitted to use
the Respimat with or without a spacer and mouthpiece, depending on preference.
End-points
The assessment of safety (together with efficacy) was a primary objective in all five trials. In the four trials
in children aged 6–17 years, the primary efficacy end-point was improvement in forced expiratory volume
in 1 s and this is what the power calculations were based on. In the trial involving children aged <6 years,
there was no formal power calculation related to an end-point, but the recruitment was considered
sufficient for the descriptive evaluation of efficacy and safety. This analysis is based on AEs occurring
between first drug inhalation and until 30 days after the last dose of trial medication, coded using the
Medical Dictionary for Regulatory Activities (MedDRA) version 18.1 (www.meddra.org). Further details
and definitions of AEs and serious AEs (SAEs) can be found in the supplementary material.
A composite end-point, grouping all AEs relating to the MedDRA-preferred term group “asthma
exacerbations and asthma-related symptoms”, from all studies in the pooled analysis was also analysed.
Preferred terms included in this analysis are listed in supplementary table E1.











Subjects 101 401 400 397 392
Male 61 (60.4) 264 (65.8) 279 (69.8) 258 (65.0) 242 (61.7)
Age years 3.0 (1–5) 9.0 (6–11) 9.0 (6–11) 14.0 (11–17) 14.0 (12–17)
Race
White 77 (76.2) 339 (84.5) 358 (89.5) 368 (92.7) 371 (94.6)
Asian 17 (16.8) 10 (2.5) 2 (0.5) 13 (3.3) 10 (2.6)
Black/African-American 7 (6.9) 7 (1.7) 5 (1.3) 14 (3.5) 8 (2.0)
American Indian/Alaska
Native
0 45 (11.2) 35 (8.8) 2 (0.5) 3 (0.8)
Hawaiian/Pacific Islander 0 0 0 0 0
Ethnicity
Hispanic/Latino 0 55 (13.7) 72 (18.0) 42 (10.6) 68 (17.3)
Never-smoker 396 (99.7) 392 (100)
No exposure to second-hand
smoke
92 (91.1) 372 (92.8) 369 (92.3) 353 (88.9) 367 (93.6)
Age at onset of asthma years 1.5±1.2 4.7±2.4 4.1±2.4 6.5±4.1 6.5±3.9
Duration of asthma years 1.3 (0.5–5.0) 4.0 (0.5–11.0) 4.8 (0.6–11.0) 8.0 (0.3–16.3) 8.0 (0.3–16.5)
Concomitant diagnoses
Allergic rhinitis 20 (19.8) 230 (57.4) 238 (59.5) 219 (55.2) 225 (57.4)
Atopic dermatitis 17 (16.8) 55 (13.7) 38 (9.5) 37 (9.3) 38 (9.7)
FEV1 % pred 84.06±10.79 81.64±11.45 82.79±10.56 79.52±11.49
FEV1 % reversibility 26.48±12.41 27.43±13.43 26.80±12.86 29.19±14.26
ACQ score# 1.868±0.31 1.966±0.36 2.03±0.43 2.13±0.43
Concomitant therapies at
baseline
LTRAs 41 (40.6) 107 (26.7) 339 (84.8) 33 (8.3) 315 (80.4)
LABAs 8 (7.9) 1 (0.2) 313 (78.3) 1 (0.3) 324 (82.7)




255.2±187.4 310.0±112.0 457.4±236.0 539.4±292.7 747.0±357.7
Data are presented as n, n (%), median (range) or mean±SD. FEV1: forced expiratory volume in 1 s; % pred: % predicted; ACQ: Asthma Control
Questionnaire; LTRA: leukotriene receptor antagonist; LABA: long-acting β2-agonist; ICS: inhaled corticosteroid.
#: interviewer-administered
ACQ in CanoTinA-asthma and VivaTinA-asthma.
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Pooled safety data are presented for the following analysis groups: all patients, and subgroups by age,
asthma severity and sex.
Additionally, the number of AEs related to asthma exacerbations and symptoms in the pooled data were
plotted by month, with data from the Southern hemisphere shifted by 6 months to align the seasons
(Northern hemisphere: June=month 6; Southern hemisphere: December=month 6).
Analyses were performed on the treated set, defined as all randomised patients who received at least one
dose of trial medication. Analyses were evaluated descriptively and no inferential statistics were performed.
Analysis of AEs related to asthma exacerbations and symptoms in the pooled data were plotted by month
as a post hoc analysis and therefore considered exploratory only.
As has been reported, each study was conducted in accordance with the amended Declaration of Helsinki.
The ethics research boards of the respective institutions approved the protocols, and signed, informed
consent was obtained from all patients and/or their parents. See original publications for further details
[18, 19, 21–23].
Results
A total of 1691 patients comprised the treated set (table 2): 560 patients received tiotropium 5 µg, 559
patients received tiotropium 2.5 µg and 572 patients received placebo. Overall, the mean exposure to study
medication was 314, 304 and 314 patient-years with tiotropium 5 µg, tiotropium 2.5 µg and placebo,
respectively.
Safety
The overall number of patients with AEs was generally comparable between treatment groups, including
placebo (table 3). Approximately half of the patients (n=879 (52%)) experienced at least one AE (n=283
(51%) receiving tiotropium 5 µg; n=286 (51%) receiving tiotropium 2.5 µg; n=310 (54%) receiving
placebo). Very few AEs led to treatment discontinuation: two in patients receiving tiotropium 5 µg and
five in patients receiving placebo. The only AE leading to discontinuation reported for more than one
patient was asthma exacerbation/worsening (two patients receiving tiotropium 5 µg and two patients
receiving placebo). The incidence of patients with investigator-defined drug-related AEs was low and
comparable between treatment groups, including placebo. None of the drug-related AEs in the tiotropium
treatment groups were serious or led to treatment discontinuation. The only AE assessed as drug related
that was reported in more than two patients was cough (one patient receiving tiotropium 5 µg; one patient
receiving tiotropium 2.5 µg; four patients receiving placebo). The overall frequency of patients that
experienced SAEs was low and comparable between treatment groups. No SAEs were considered drug
related or led to treatment discontinuation. The only SAEs reported for more than two patients were
asthma exacerbation/worsening/crisis (five patients receiving tiotropium 5 µg; three patients receiving
tiotropium 2.5 µg; five patients receiving placebo) and appendicitis (two patients receiving tiotropium 5 µg;
two patients receiving tiotropium 2.5 µg; one patient receiving placebo). No deaths occurred during any of
the trials.
Consistent with the disease profile, the most frequently reported AEs, reported by ⩾5% of patients, were
asthma exacerbation/worsening, decreased peak expiratory flow (PEF) rate, nasopharyngitis/rhinopharyngitis
TABLE 3 Overview of patients reporting adverse events (AEs) in the pooled population: treated
set (treatment plus 30 days following treatment)
Tiotropium 5 µg Tiotropium 2.5 µg Placebo
Subjects 560 559 572
Any AEs 283 (50.5) 286 (51.2) 310 (54.2)
Drug-related AEs 7 (1.3) 1 (0.2) 8 (1.4)
AEs leading to discontinuation 2 (0.4) 0 5 (0.9)
Serious AEs 10 (1.8) 8 (1.4) 13 (2.3)
AEs reported in ⩾5% and ⩾10 patients#
Asthma exacerbation/worsening 110 (19.6) 115 (20.6) 143 (25.0)
Decreased peak expiratory flow rate 55 (9.8) 64 (11.4) 68 (11.9)
Nasopharyngitis/rhinopharyngitis 44 (7.9) 46 (8.2) 49 (8.6)
Viral respiratory tract infection 27 (4.8) 24 (4.3) 30 (5.2)
Data are presented as n or n (%). Percentages are calculated using total number of patients per treatment
as the denominator. #: in at least one treatment group.
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and viral respiratory tract infection (table 3; AEs reported by ⩾2% of patients are shown in supplementary
table E2). These were reported by a similar proportion of patients in the tiotropium and placebo groups,
except asthma exacerbation/worsening, which was reported by fewer patients in the tiotropium treatment
groups.
The frequency of patients reporting a composite end-point, grouping all AEs related to asthma
exacerbations and asthma symptoms, was lower in the tiotropium treatment groups than with placebo
(placebo: 217 patients with event (37.9%); tiotropium 5 µg: 177 patients with event (31.6%), rate ratio over
placebo 0.76 (95% CI 0.63–0.93); tiotropium 2.5 µg: 195 patients with event (34.9%), rate ratio over
placebo 0.87 (95% CI 0.72–1.05)). A description of safety topics of interest is available in the
supplementary material.
Subgroups by age
Safety in the different age categories was generally comparable with the pooled population (table 4). The
lower proportion of patients with asthma exacerbation/worsening as an AE in the tiotropium groups
compared with the placebo group was most prominently observed in patients aged 1–5 years (6.5% for
tiotropium 5 µg; 13.9% for tiotropium 2.5 µg; 29.4% for placebo), with similar trends in patients aged
6–11 years (26.4% for tiotropium 5 µg; 25.5% for tiotropium 2.5 µg; 32.8% for placebo) and 12–17 years
(14.4% for tiotropium 5 µg; 16.3% for tiotropium 2.5 µg; 16.8% for placebo).
No SAEs were reported in patients treated with tiotropium in the 1–5-year-old group and no AEs in this
age group led to discontinuation in any treatment group (table 4; SAEs by age are shown in
supplementary table E3). Asthma was the only AE preferred term reported in ⩾5%, or in 10 or more
patients, in any of the treatment groups.
An analysis of pooled data from studies with patients aged ⩾6 years is detailed in supplementary table E4.
TABLE 4 Overview of patients reporting adverse events (AEs) by age subgroups: treated set
(treatment plus 30 days following treatment)
Tiotropium 5 µg Tiotropium 2.5 µg Placebo
Age 1–5 years [23]
Subjects 31 36 34
Any AEs 18 (58.1) 20 (55.6) 25 (73.5)
Drug-related AEs 2 (6.5) 0 2 (5.9)
AEs leading to discontinuation 0 0 0
Serious AEs 0 0 3 (8.8)
AEs reported in ⩾5% and ⩾10 patients#
Asthma exacerbation/worsening 2 (6.5) 5 (13.9) 10 (29.4)
Age 6–11 years [21, 22]
Subjects 265 271 265
Any AEs 138 (52.1) 145 (53.5) 155 (58.5)
Drug-related AEs 1 (0.4) 0 4 (1.5)
AEs leading to discontinuation 2 (0.8) 0 2 (0.8)
Serious AEs 5 (1.9) 5 (1.8) 8 (3.0)
AEs reported in ⩾5% and ⩾10 patients#
Asthma exacerbation/worsening 70 (26.4) 69 (25.5) 87 (32.8)
Decreased peak expiratory flow rate 44 (16.6) 46 (17.0) 47 (17.7)
Nasopharyngitis/rhinopharyngitis 18 (6.8) 21 (7.7) 24 (9.1)
Age 12–17 years [18, 19]
Subjects 264 252 273
Any AEs 127 (48.1) 121 (48.0) 130 (47.6)
Drug-related AEs 4 (1.5) 1 (0.4) 2 (0.7)
AEs leading to discontinuation 0 0 3 (1.1)
Serious AEs 5 (1.9) 3 (1.2) 2 (0.7)
AEs reported in ⩾5% and ⩾10 patients#
Asthma exacerbation/worsening 38 (14.4) 41 (16.3) 46 (16.8)
Nasopharyngitis/rhinopharyngitis 24 (9.1) 18 (7.1) 20 (7.3)
Decreased peak expiratory flow rate 11 (4.2) 18 (7.1) 21 (7.7)
Viral respiratory tract infection 11 (4.2) 11 (4.4) 14 (5.1)
Data are presented as n or n (%). Percentages are calculated using total number of patients per treatment
as the denominator. #: in at least one treatment group.
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Subgroups by asthma severity
The safety in the different asthma severity categories was generally comparable with the pooled population
(table 5). However, compared with the pooled population, more patients with moderate asthma reported at
least one AE and fewer patients with severe asthma reported at least one AE. This is most likely due to the
longer duration of the studies in moderate asthma (48 weeks for moderate asthma versus 12 weeks for
severe asthma). Of note, in patients with severe asthma, decreased PEF rate was reported by fewer patients
in the tiotropium groups than in the placebo group.
Subgroup analyses of LABA and LTRA use at randomisation were also performed; as expected, the results
were consistent with the subgroup analyses by severity, since LABAs/LTRAs were predominantly taken by
patients with more severe asthma.
Subgroups by sex
In an analysis of AEs by sex, there were fewer females than males in each treatment group; proportionally,
slightly fewer females reported AEs compared with males, particularly in the tiotropium 5 µg and placebo
groups, with no notable differences in the proportion of patients with drug-related AEs or AEs leading to
discontinuation (table 6). As in the overall analysis, the frequency of patients experiencing SAEs was low
and comparable between treatment groups.
Analysis of seasonal asthma worsening
When analysed by month, reports of AEs related to asthma exacerbations and symptoms were greatest in
the placebo group in the spring, autumn and winter (figure 1), and lowest in the summer. With both
doses of tiotropium, spring and autumn peaks were reduced. An analysis by month of reported AEs
relating to asthma exacerbations and symptoms from studies with patients aged ⩾6 years is detailed in
supplementary figure E1.
Discussion
In this comprehensive pooled analysis, tiotropium was well tolerated, with a safety profile comparable with
placebo. Specifically, the incidence of patients reporting drug-related AEs, AEs leading to discontinuation,
SAEs and AEs commonly associated with anticholinergic therapy was low and generally balanced between
treatment groups, including placebo. Baseline demographics and disease characteristics were comparable
between the treatment groups within each trial (table 2). Pharmacokinetic data from the 1–5-year-old
TABLE 5 Overview of patients reporting adverse events (AEs) in subgroups by asthma severity:
treated set (treatment plus 30 days following treatment)
Tiotropium 5 µg Tiotropium 2.5 µg Placebo
Moderate asthma [18, 22]
Subjects 269 260 269
Any AEs 166 (61.7) 165 (63.5) 171 (63.6)
Drug-related AEs 4 (1.5) 1 (0.4) 3 (1.1)
AEs leading to discontinuation 0 0 2 (0.7)
Serious AEs 4 (1.5) 5 (1.9) 8 (3.0)
AEs reported in ⩾5% and ⩾10 patients#
Asthma exacerbation/worsening 69 (25.7) 76 (29.2) 89 (33.1)
Decreased peak expiratory flow rate 35 (13.0) 40 (15.4) 35 (13.0)
Nasopharyngitis/rhinopharyngitis 31 (11.5) 28 (10.8) 30 (11.2)
Viral respiratory tract infection 18 (6.7) 19 (7.3) 19 (7.1)
Respiratory tract infection 15 (5.6) 16 (6.2) 21 (7.8)
Severe asthma [19, 21]
Subjects 260 263 269
Any AEs 99 (38.1) 101 (38.4) 114 (42.4)
Drug-related AEs 1 (0.4) 0 3 (1.1)
AEs leading to discontinuation 2 (0.8) 0 3 (1.1)
Serious AEs 6 (2.3) 3 (1.1) 2 (0.7)
AEs reported in ⩾5% and ⩾10 patients#
Asthma exacerbation/worsening 39 (15.0) 34 (12.9) 44 (16.4)
Decreased peak expiratory flow rate 20 (7.7) 24 (9.1) 33 (12.3)
Nasopharyngitis/rhinopharyngitis 11 (4.2) 11 (4.2) 14 (5.2)
Data are presented as n or n (%). Percentages are calculated using total number of patients per treatment
as the denominator. #: in at least one treatment group.
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group (including those using the valved holding chamber) have previously been shown to be comparable
with results from 6–17-year-old groups when adjusted for body size, indicating adequacy of systemic
exposure to tiotropium [29].
Efficacy data suggest that tiotropium is an effective add-on to ICS, with or without additional controller
therapies, in children and adolescents with asthma [16–19, 22, 23]. The results of this pooled analysis
provide additional evidence of the favourable safety profile of tiotropium in children and adolescents with
symptomatic asthma (aged 1–17 years) [28, 29].
An important finding is that AEs related to asthma symptoms and exacerbations were reported by fewer
patients in the tiotropium 5 µg treatment group compared with the placebo, with particular effect in
reducing spring and autumn seasonal peaks. While reported as a safety parameter, this signal may also be
considered in terms of efficacy, particularly in very young children with asthma, where validated tools for
the assessment of efficacy in clinical trials are currently limited [23]. It is interesting to note that this effect
TABLE 6 Overview of patients reporting adverse events (AEs) in subgroups by sex: treated set
(treatment plus 30 days following treatment)
Tiotropium 5 µg Tiotropium 2.5 µg Placebo
Males
Subjects 365 373 366
Any AEs 195 (53.4) 190 (50.9) 201 (54.9)
Drug-related AEs 5 (1.4) 0 5 (1.4)
AEs leading to discontinuation 2 (0.5) 0 3 (0.8)
Serious AEs 7 (1.9) 6 (1.6) 4 (1.1)
AEs reported in ⩾5% and ⩾10 patients#
Asthma exacerbation/worsening 75 (20.5) 73 (19.6) 94 (25.7)
Decreased peak expiratory flow rate 38 (10.4) 49 (13.1) 44 (12.0)
Nasopharyngitis/rhinopharyngitis 29 (7.9) 34 (9.1) 34 (9.3)
Viral respiratory tract infection 16 (4.4) 14 (3.8) 22 (6.0)
Respiratory tract infection 14 (3.8) 11 (2.9) 20 (5.5)
Females
Subjects 195 186 206
Any AEs 88 (45.1) 96 (51.6) 109 (52.9)
Drug-related AEs 2 (1.0) 1 (0.5) 3 (1.5)
AEs leading to discontinuation 0 0 2 (1.0)
Serious AEs 3 (1.5) 2 (1.1) 9 (4.4)
AEs reported in ⩾5% and ⩾10 patients#
Asthma exacerbation/worsening 35 (17.9) 42 (22.6) 49 (23.8)
Decreased peak expiratory flow rate 17 (8.7) 15 (8.1) 24 (11.7)
Nasopharyngitis/rhinopharyngitis 15 (7.7) 12 (6.5) 15 (7.3)
Viral respiratory tract infection 11 (5.6) 10 (5.4) 8 (3.9)
Data are presented as n or n (%). Percentages are calculated using total number of patients per treatment
as the denominator. #: in at least one treatment group.
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FIGURE 1 Number of reported adverse events (AEs) related to asthma exacerbations and symptoms over 12 months in the pooled population.
a) Tiotropium 5 µg and placebo groups. b) Tiotropium 2.5 µg and placebo groups. Data from the Southern hemisphere shifted by 6 months to align
the seasons (Northern hemisphere: June=month 6; Southern hemisphere: December=month 6).
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with tiotropium added to ICS/LABA has been observed with other interventions, including ICS/LABA
combinations [30] and biologicals [31]. As long-term asthma exacerbation trials in paediatric patients
remain ethically challenging, this analysis highlights an alternative end-point to investigate such efficacy in
children. These data also highlight the importance of trial timing to account for seasonal exacerbation
peaks when a 12-month study length is not practical. However, since this finding is exploratory, it should
be confirmed in a predefined study that could also investigate which age subgroup had the greatest benefit.
Reported class effects of anticholinergics include upper respiratory tract infections, tachycardia, dry mouth
and other gastrointestinal complications, as well as urinary retention and urinary tract infections [32–35].
The incidence of patients reporting these AEs was low in the present analysis and, overall, the safety
profile of tiotropium was comparable with placebo in all trials reported here [29]. Notably, cardiac events
were reported by only two patients and they were both in the placebo group.
Within analyses of population subgroups defined by age, asthma severity, sex and LABA/LTRA use at
baseline, the proportions of patients reporting AEs and SAEs were generally comparable between
treatment groups, including placebo. This is further supported by a recent systematic review of the efficacy
and safety of tiotropium in children aged 6–11 years with symptomatic moderate-to-severe asthma [36].
The authors concluded that none of the three studies included in the analysis (two of which are included
in the analysis presented here) showed an increase in the rate of AEs or SAEs reported in the tiotropium
group compared with placebo [36].
A major strength of this analysis is that all the trials were placebo controlled with comparable design and
therefore provide the most valid comparison for assessing AEs. Furthermore, all patients continued to receive
their usual maintenance therapies (except for LABA in patients with moderate asthma), allowing investigation
of tiotropium in varied settings of concurrent medications and thereby making it as representative of
treatment in a real-world setting as is achievable in a clinical trial setting. The patient sample was very large
and covered a wide age range; patients were recruited from various populations and geographical locations,
including a high proportion of Latin American patients (a population noted to have a high incidence and a
higher severity of childhood asthma). Limitations of our pooled analysis included the difference in duration of
the five included trials (two at 48 weeks and three at 12 weeks) and that none were >48 weeks.
Conclusions
Once-daily tiotropium as add-on to at least ICS maintenance treatment in patients aged 1–17 years with
symptomatic asthma at different GINA treatment steps is an addition to current treatment options, with a
safety and tolerability profile comparable with that of placebo. No new safety signals were identified in this
comprehensive analysis, which supports the favourable risk–benefit profile of once-daily tiotropium as
add-on to maintenance ICS with or without additional controllers in paediatric patients with symptomatic
asthma. Moreover, a reduction in patients reporting AEs related to asthma exacerbations and asthma
symptoms was observed with tiotropium 5 µg, especially related to seasonal peaks in exacerbations.
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